InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,732.29
(
-0.10%
)
US TECH 100
19,405.60
(
-0.33%
)
Dow Jones
42,154.69
(
-0.37%
)
Brent Oil
71.86
(
0.21%
)
Bitcoin
63,401.88
(
-3.39%
)
Post# of 253255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120512
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 89680

Tuesday, 01/26/2010 10:15:37 PM

Tuesday, January 26, 2010 10:15:37 PM

Post# of 253255
Well, we now have a contest for TLR9 agonsists in HCV: the other one is IMO-2125 from IDRA (#msg-44746537). From the DVAX PR you posted:

A dose-dependent antiviral response, with 100% of patients at the highest dose experiencing a greater than one (1) log reduction in viral load…

What the PR does not say is that patients in the highest-dose arm had a 1-log or greater drop in viral load at the end of four weeks of treatment. Thus, some (or all) of these patients might have experienced a viral rebound during the 4-week treatment period, which would obviously be bearish for this program.

I’ll add an entry for SD-101 in the “HCV: Most Likely to Succeed” post.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up